ACP Issues Clinical Guideline for Statin Use in Persons With HIV
By Elana Gotkine HealthDay Reporter
THURSDAY, May 29, 2025 -- In a clinical guideline issued by the American College of Physicians and published online May 27 in the Annals of Internal Medicine, recommendations are presented for the use of statins among persons with HIV (PWH).
Craig Beavers, Pharm.D., from the University of Kentucky College of Pharmacy in Lexington, and colleagues developed statin therapy recommendations for PWH. A writing group of 10 members was convened; data were reviewed from the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), other studies, and current guidelines.
The U.S. Department of Health and Human Services Panel for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (ARV Guidelines Panel) issued strong recommendations for initiation of statin therapy among PWH with a 10-year atherosclerotic cardiovascular disease (ASCVD) risk score of 5 percent or higher, who derived the greatest benefit from statins in REPRIEVE. The panel favored statins for patients with a 10-year ASCVD risk score below 5 percent, but recommended patient-clinician risk discussions that accounted for additional HIV-related risk factors that could potentially increase ASCVD risk.
"There remain important clinical questions in the management of CVD risk among PWH, including further improvements in risk stratification, as well as additional ASCVD prevention strategies focused on reducing residual risk associated with inflammation," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
FDA Approves Twice-Yearly Yeztugo for Preexposure Prophylaxis to Cut HIV Risk
FRIDAY, June 20, 2025 -- The U.S. Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to...
Anal Cancer Screening Cost-Effective for HIV+ Men Who Have Sex With Men ≥35 Years of Age
TUESDAY, June 17, 2025 -- For men who have sex with men (MSM) with HIV, aged 35 years or older, anal cancer screening is cost-effective, according to a study published online June...
Initiation of HIV PrEP in Young Adults Rose in Recent Years
TUESDAY, June 3, 2025 -- Dispensing and initiation of HIV preexposure prophylaxis (PrEP) among young adults increased from 2016 through 2023, according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.